LXEO vs MBX: fair value comparison
Lexeo Therapeutics, Inc. and MBX Biosciences, Inc. · Updated 2026-10-19
LXEO has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. MBX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, LXEO currently ranks higher by quality score.
| LXEO | MBX | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $2.64 | $49.61 |
| 12-month range | $2.63–$10.63 | $16.13–$70.70 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #248 of 301 Healthcare | #250 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| RSI zone | Oversold | Oversold |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The bottom quarter | The upper-middle quarter |
Full single-stock breakdowns: LXEO fair value analysis · MBX fair value analysis